Shares of GeneDx Holdings (WGS) experienced a significant drop during Thursday's trading session, plummeting 5.08% as investors reacted to a series of analyst reports from Wells Fargo. The genetic testing company's stock faced downward pressure following a notable reduction in its price target by the financial services firm.

Wells Fargo maintained its Hold rating on GeneDx Holdings but substantially lowered its price target from $105 to $78. This adjustment represents a 25.7% decrease in the expected value of the stock, signaling a more cautious outlook on the company's near-term prospects. Additionally, the firm reiterated its Equal-Weight rating on WGS, further emphasizing a balanced but conservative stance.

The market's sharp reaction to these analyst actions underscores the influence that Wall Street opinions can have on investor sentiment. While Wells Fargo's maintained Hold and Equal-Weight ratings suggest a neutral position, the significant cut in the price target appears to have triggered a sell-off among shareholders. As GeneDx Holdings continues to navigate the competitive landscape of genetic testing and diagnostics, investors will likely keep a close eye on future analyst reports and the company's ability to meet or exceed market expectations.